Cathie Wood continues buying Beam Therapeutics (BEAM)
BEAM Beam Therapeutics Inc
$23.47 -5.10%
View chart & analysis → - 1Cathie Wood's ARK ETFs make additional purchases of Beam Therapeutics (BEAM) shares
- 2ARK Genomic Revolution (ARKG) added $2.8 million on October 12 and 13, bringing total holdings to $220.4 million
- 3Beam holds base editing technology, reported $32.2 million in revenue for the first half of the year, and has $1.15 billion in cash to fund operations until mid-2029
So what's the key point?
The ARK fund led by Cathie Wood bought more shares of the gene-editing company Beam Therapeutics. While the company is not yet profitable, it stated that its current cash reserves can sustain operations until mid-2029.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.